Melanoma: From incurable beast to a curable bet. The success of immunotherapy

Maria Libera Ascierto, Ignacio Melero, Paolo A. Ascierto

Research output: Contribution to journalArticle

Abstract

After Coley's observation in 1891 of tumor regression in a patient who developed a postoperative infection, the field of immunotherapy is finally reborn. Avoiding immune destruction is now considered a hallmark of cancer and the immunotherapy arena has exploded with the recent advances demonstrating an improvement in survival and a durability of response in patients with different cancer types which translates into improved overall survival benefit. Here, we provide an overview of the main immuneoncology treatment strategies that, either alone or in combination, are undergoing clinical development. Namely, we will refer to those immunotherapeutic strategies that include adoptive transfer of ex vivo activated T cells, immunomodulatory monoclonal antibodies and cancer vaccines. Our major focus will be to describe these approaches in melanoma, a cancer type transformed by immunotherapy into a potentially curable disease.

Original languageEnglish
Article number152
JournalFrontiers in Oncology
Volume5
Issue numberJUN
DOIs
Publication statusPublished - 2015

Fingerprint

Immunotherapy
Melanoma
Neoplasms
Cancer Vaccines
Survival
Adoptive Transfer
Monoclonal Antibodies
Observation
T-Lymphocytes
Infection
Therapeutics

Keywords

  • Adoptive T cell therapy
  • Combination therapy
  • Immunomodulatory antibodies
  • Immunotherapy
  • Melanoma
  • Vaccination

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Melanoma : From incurable beast to a curable bet. The success of immunotherapy. / Ascierto, Maria Libera; Melero, Ignacio; Ascierto, Paolo A.

In: Frontiers in Oncology, Vol. 5, No. JUN, 152, 2015.

Research output: Contribution to journalArticle

@article{f5e12875cd484e79a9a983a08f53a141,
title = "Melanoma: From incurable beast to a curable bet. The success of immunotherapy",
abstract = "After Coley's observation in 1891 of tumor regression in a patient who developed a postoperative infection, the field of immunotherapy is finally reborn. Avoiding immune destruction is now considered a hallmark of cancer and the immunotherapy arena has exploded with the recent advances demonstrating an improvement in survival and a durability of response in patients with different cancer types which translates into improved overall survival benefit. Here, we provide an overview of the main immuneoncology treatment strategies that, either alone or in combination, are undergoing clinical development. Namely, we will refer to those immunotherapeutic strategies that include adoptive transfer of ex vivo activated T cells, immunomodulatory monoclonal antibodies and cancer vaccines. Our major focus will be to describe these approaches in melanoma, a cancer type transformed by immunotherapy into a potentially curable disease.",
keywords = "Adoptive T cell therapy, Combination therapy, Immunomodulatory antibodies, Immunotherapy, Melanoma, Vaccination",
author = "Ascierto, {Maria Libera} and Ignacio Melero and Ascierto, {Paolo A.}",
year = "2015",
doi = "10.3389/fonc.2015.00152",
language = "English",
volume = "5",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - Melanoma

T2 - From incurable beast to a curable bet. The success of immunotherapy

AU - Ascierto, Maria Libera

AU - Melero, Ignacio

AU - Ascierto, Paolo A.

PY - 2015

Y1 - 2015

N2 - After Coley's observation in 1891 of tumor regression in a patient who developed a postoperative infection, the field of immunotherapy is finally reborn. Avoiding immune destruction is now considered a hallmark of cancer and the immunotherapy arena has exploded with the recent advances demonstrating an improvement in survival and a durability of response in patients with different cancer types which translates into improved overall survival benefit. Here, we provide an overview of the main immuneoncology treatment strategies that, either alone or in combination, are undergoing clinical development. Namely, we will refer to those immunotherapeutic strategies that include adoptive transfer of ex vivo activated T cells, immunomodulatory monoclonal antibodies and cancer vaccines. Our major focus will be to describe these approaches in melanoma, a cancer type transformed by immunotherapy into a potentially curable disease.

AB - After Coley's observation in 1891 of tumor regression in a patient who developed a postoperative infection, the field of immunotherapy is finally reborn. Avoiding immune destruction is now considered a hallmark of cancer and the immunotherapy arena has exploded with the recent advances demonstrating an improvement in survival and a durability of response in patients with different cancer types which translates into improved overall survival benefit. Here, we provide an overview of the main immuneoncology treatment strategies that, either alone or in combination, are undergoing clinical development. Namely, we will refer to those immunotherapeutic strategies that include adoptive transfer of ex vivo activated T cells, immunomodulatory monoclonal antibodies and cancer vaccines. Our major focus will be to describe these approaches in melanoma, a cancer type transformed by immunotherapy into a potentially curable disease.

KW - Adoptive T cell therapy

KW - Combination therapy

KW - Immunomodulatory antibodies

KW - Immunotherapy

KW - Melanoma

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=84934288831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934288831&partnerID=8YFLogxK

U2 - 10.3389/fonc.2015.00152

DO - 10.3389/fonc.2015.00152

M3 - Article

AN - SCOPUS:84934288831

VL - 5

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - JUN

M1 - 152

ER -